| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 134.1 | 131.3 | 107.9 |
| Other income | -0.3 | 1.7 | 0.7 |
| Total income | 133.8 | 133.1 | 108.6 |
| Profit before exceptional items & tax | 16.6 | 17.7 | 2.0 |
| Profit before tax | 16.6 | 17.7 | 2.0 |
| Net profit | 10.3 | 15.2 | 1.0 |
| Operating margin | 12.4% | 13.3% | 1.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +930.00% |
|---|---|
| Net profit, quarter on quarter | -32.20% |
| Revenue, year on year | +24.30% |
NSE results filing, NSE: TATVA. Figures extracted from the filing.
Tatva Chintan Pharma Chem Ltd: key numbers
- Share price
- ₹1,793.20
- Market cap
- ₹4,195 Cr
- Revenue (annual)
- ₹505.9 Cr
- Net profit (annual)
- ₹42.05 Cr
- P/E (TTM)
- 81.6×Sector 37.5×
- Promoter holding
- 72.02%+0.00% QoQ
- FII holding
- 3.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Tatva Chintan Pharma Chem Ltd
All →Tatva Chintan Pharma Chem Annual General Meeting
The company held its 30th Annual General Meeting on September 25, 2026. Shareholders considered and approved items including financial statements and director re-appointments.
Tatva Chintan Pharma Chem Credit Rating
CRISIL Ratings upgraded Tatva Chintan's long-term bank facilities to CRISIL A-/Stable and short-term facilities to CRISIL A2+. This upgrade reflects the company's improved credit profile.
Tatva Chintan Pharma Chem Investor Presentation: Key Takeaways
Tatva Chintan reported strong Q1 FY27 results with 43% YoY revenue growth. Strategy focuses on expanding SDA for Euro 7 standards and commercializing new pharma/semiconductor molecules.
- Call
- Guides 30% growth
Tatva Chintan Pharma Chem Earnings Call: Key Takeaways
Tatva Chintan reported strong Q1FY27 performance with 43% YoY revenue growth to ₹1,671 Mn. Strategy focuses on green chemistry, R&D in continuous flow, and electrolysis for SDAs.
Tatva Chintan Pharma Chem Earnings Call: Key Takeaways
Tatva Chintan reported Q4 FY26 revenue of ₹1,341 million (up 24% YoY) and EBITDA of ₹281 million (up 214% YoY), driven by improved product mix and operating leverage.
Tatva Chintan Pharma Chem Earnings Call: Key Takeaways
Tatva Chintan reported FY26 revenue of ₹5,059 Mn, up 32% YoY. Growth driven by SDA segment expansion and 'green' chemistry adoption.